Table 2 Risk factors of oral mucositis.

From: Female sex as an independent prognostic factor in the development of oral mucositis during autologous peripheral stem cell transplantation

 

Total patients

Lymphoma

Myeloma multiplex

OR (95% CI)

p

OR (95% CI)

p

OR (95% CI)

p

Univariable analysis

Age at the time of Tx (years)

0.988 (0.964–1.015)

0.371

0.988 (0.952–1.025)

0.526

1.024 (0.970–1.082)

0.384

Dg-Tx time interval (months)

1.004 (0.991–1.016)

0.542

0.999 (0.985–1.013)

0.897

0.999 (0.970–1.029)

0.950

Amount of stem cells

(106/body mass kg)

0.967 (0.830–1.127)

0.668

1.021 (0.81–1.285)

0.863

0.908 (0.731–1.127)

0.382

Viability (%)

1.022 (0.959–1.090)

0.503

1.016 (0.925–1.116)

0.744

1.062 (0.963–1.172)

0.226

Amount of viable cells

(106/body mass kg)

0.965 (0.813–1.146)

0.688

1.025 (0.787–1.335)

0.853

0.909 (0.715–1.157)

0.439

MNC

(108/body mass kg)

1.033 (0.930–1.147)

0.547

1.034 (0.89–1.2)

0.664

0.989 (0.833–1.166)

0.868

ANC < 0.5 G/L (days)

1.461 (1.225–1.744)

< 0.001

1.584 (1.134–2.214)

0.007

1.39 (1.09–1.773)

0.008

THR < 20 G/L (days)

1.178 (1.078–1.288)

< 0.001

1.279 (1.043–1.57)

0.018

1.128 (1.009–1.262)

0.034

LDH (U/L)

1.004 (1–1.009)

0.067

1.005 (0.998–1.012)

0.168

1.002 (0.996–1.008)

0.526

Female versus male

1.969 (1.052–3.687)

0.034

5.294 (1.418–19.762)

0.013

1.462 (0.67–3.194)

0.340

Advanced stage at the time of the diagnosis

1.447 (0.545–3.842)

0.458

0.571 (0.054–6.079)

0.643

1.120 (0.278–4.508)

0.873

Advanced stage before transplantation

1.143 (0.594–2.198)

0.689

0.553 (0.19–1.606)

0.276

1.828 (0.778–4.297)

0.166

Infection

1.901 (0.894–1.041)

0.095

1.122 (0.396–3.178)

0.828

2.608 (0.795–8.554)

0.114

HL-NHL

1.455 (0.468–4.524)

0.518

1.455 (0.468–4.524)

0.518

–

–

MM-NHL

0.563 (0.282–1.124)

0.103

–

–

–

–

L-MM

1.969 (1.052–3.687)

0.034

–

–

–

–

Stage of missing of B symptoms

–

–

7.000 (1.085–45.16)

0.041

  

IgA versus IgG

–

–

–

–

2.766 (0.984–7.773)

0.054

Kappa versus lambda

–

–

–

–

0.644 (0.291–1.425)

0.277

Dosis of melphalan (≥ 200 mg/m2)

–

–

–

–

1.046 (0.301–3.629)

0.944

MM pretreatment

–

–

–

–

1.559 (0.464–5.231)

0.472

Multivariable analysis

ANC ˂ 0.5 G/L (days)

1.492 (1.228–1.813)

< 0.001

1.476 (1.061–2.052)

0.021

1.39 (1.09–1.773)

0.008

Gender

2.301 (1.124–4.714)

0.023

4.190 (1.081–16.240)

0.038

  
  1. p < 0.05 was considered significant. p values with bold are significant, while with italic, are non-significant, but close to it.
  2. Statistical analysis: binary logistic regression was used.
  3. ANC absolute neutrophil count, Dg diagnosis, HL Hodgkin lymphoma, IgA immunoglobulin A, IgG immunoglobulin G, L lymphoma, LDH lactate-dehydrogenase, MM Multiple myeloma, MNC mononuclear cells, n numero, NHL Non-Hodgkin’s lymphoma, OM oral mucositis, THR thrombocyte count, Tx transplantation.
Back to article page